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Background and Aims:  Alcoholic cirrhosis (AC) is a major cause of liver-related morbidity and 
mortality in the United States (US). Rising rates of alcohol use disorders in the US will likely result in 
more alcoholic liver disease.  Our aim was to determine the prevalence, healthcare utilization, and 
costs of AC among privately insured persons in the US.  Methods: We collected data from persons 
aged 18-64 with AC (identified by ICD-9/ICD-10 codes) enrolled in the Truven MarketScan 
Commercial Claims and Encounters database (2009-2015).  We determined yearly prevalence, 
weighted to the national employer-sponsored, privately insured population.  Using competing risk 
analysis, we estimated event rates for portal hypertensive complications and estimated the 
association between alcoholic cirrhosis and costs as well as admissions and readmissions. Results: 
294,215 people had cirrhosis in 2015 and 105,871 (36%) had AC. Mean age at AC diagnosis was 
53.5 years. 32% were women.  Over the 7 years queried, estimated national cirrhosis prevalence 
rose from 0.19% to 0.27% (p<0.001) and from 0.07% to 0.10% (p<0.001) for AC.  Compared to non-
AC, AC enrollees were significantly more likely to have portal hypertensive complications at 
diagnosis, and higher yearly cirrhosis and alcohol-related admissions (25 excess cirrhosis admissions 
and 6.3 excess alcohol-related admissions per 100 enrollees) as well as all-cause readmissions.  
Per-person costs in the first year after diagnosis nearly doubled for AC versus non-AC persons (US$ 
44,835 vs 23,319). Conclusion: In a nationally representative cohort of privately insured persons, AC 
enrollees were disproportionately sicker at presentation, admitted and readmitted more often, and 
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Alcoholic liver disease (ALD) resulting from chronic heavy alcohol consumption is a large and growing 
problem in the United States (US), making it the second leading indication for liver transplantation(1-
3). Worldwide, ALD is thought to be responsible for nearly half of the liver-related mortality(4,5). ALD 
is a spectrum of liver disease, ranging from mild fatty liver to more severe forms, such as alcoholic 
cirrhosis (AC) and alcoholic hepatitis. Chronic heavy alcohol consumption results in AC and portal 
hypertension, causing high rates of variceal bleeding, ascites, hepatic encephalopathy, and death(6-
8).  Alcohol abstinence frequently improves liver function, portal hypertensive complications, and 
mortality, even in advanced stages of AC or alcoholic hepatitis(9,10).  
 
Unfortunately, alcohol consumption is increasing in the US.  From 2001 to 2012, the prevalence of 
alcohol use disorder (AUD) increased by 50% in the US general population (from 8.5% to 13%), 
affecting nearly 1 in 6 Americans(11). This increase disproportionately affected women, older adults, 
and persons of lower socioeconomic status(11).  The annual rates of specialty addiction care use in 
the US are approximately 8% and are subject to variable degrees of coverage by insurance 
payors(12).  The impact of these trends is compounded by the increasing rates of cirrhosis-related 
death already affecting several segments of the US population(13).  Given these increased rates of 
AUD, the overall incidence of AC will likely increase, magnifying the importance of accurate data on 
AC prevalence, costs, hospitalizations, and complications.  
 
Prior large US dataset analyses have focused on non-cirrhotic ALD, with estimated prevalence 
ranging from 2-2.5%(14). Another analysis from a large national dataset, inclusive of all insurance 
types, assessed the prevalence of all-cause cirrhosis to be 0.27%(15). In the Veteran’s Administration 
(VA) system, the prevalence of all-cause cirrhosis is high at 1.0%, but this data cannot be generalized 
to the US population owing to low female representation and differences in socio-economic status 
and comorbidities(18).  These studies, however, did not provide direct estimates of AC in the privately 
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insured US population.  While many European databases include comprehensive population data 
from birth to death, US health insurance data is fragmented between private insurance, Medicare and 
Medicaid, the VA, and the uninsured, making national estimates of AC burden more challenging. 
 
A correct assessment of AC’s healthcare burden is essential to create sensible policy initiatives, 
design effective treatment protocols, and appropriately allocate resources.  Since half of the US is 
privately insured (employer-based being by far the most common), large databases representative of 
this population are useful in efforts to estimate AC’s broader impact and burden in the US. Our aim 
was to query a large, nationally representative cohort of employer-sponsored insurance claims to 




This study was reviewed by the Institutional Review Board of the University of Michigan and was 
exempted from IRB review.  We queried the 2009-2015 MarketScan Commercial Claims and 
Encounters (CCAE) database, a large administrative claims database maintained by Truven 
Analytics.  The database’s structure permits a researcher to follow a single enrollee through multiple 
years of enrollment across inpatient and outpatient settings.  MarketScan is one of the largest and 
most comprehensive private insurance administrative datasets that is widely used in healthcare 
delivery, epidemiology, and economic burden research(19-23).  Drawing on all regions of the US, it 
contains private, employer-based insurance claims from more than 100 insurers, catalogs nearly 500 
million claims from over 100 million enrollees and their dependents, and calculates population-level 
weights so research findings can be generalized to the approximately 150 million privately insured US 
adults.  MarketScan nearly approximates the entire population with employer-sponsored insurance 
(ESI), which, in 2012, numbered 115,510,639 persons between the ages of 18-64.   
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Study enrollees from MarketScan data (2009-2015) were between the ages of 18-64 and had at least 
one diagnosis code for cirrhosis (571.2 or 571.5) with at least 1 year of continuous enrollment, 
inclusive of the index cirrhosis diagnosis(24) (see Appendix A).  All study data were restricted to the 
continuous enrollment period containing the cirrhosis diagnosis. Cirrhosis diagnosis was determined 
by International Classification of Diseases 9th revision (ICD-9) or 10th revision (ICD-10) cirrhosis 
codes identified during the study period.  Because cirrhosis complications, such as variceal bleeding 
or ascites, could be coded prior to a code for cirrhosis, the index cirrhosis diagnosis date was defined 
as the earliest date on which a diagnosis code for a portal hypertensive complication (portal 
hypertension, ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, varices with or 
without bleeding, hepatic encephalopathy) or cirrhosis was observed (see Appendix A).  Single ICD-9 
codes for cirrhosis and its complications have been validated in administrative data with positive 
predictive values of 80% or greater (24,25).  
 
Using published criteria(18), an AC diagnosis was defined in our study as a discrete AC diagnosis 
code or a general, non-alcohol-related cirrhosis code plus either an alcohol use code or a code for an 
alcohol-related comorbidity (see Appendix A for list of codes used).  Enrollees who met criteria for 
comorbid AC and hepatitis C (HCV) or other liver disease were included in the AC cohort.  Non-AC 
was defined as the presence of a non-alcohol-related cirrhosis code, regardless of etiology, without 
any alcohol-related comorbidity diagnoses.  Comorbidities were ascertained using ICD-9 and ICD-10 
codes (see Appendix A) and Elixhauser scores were calculated excluding the liver and alcohol 
categories(26).  Decompensated cirrhosis was defined by a cirrhosis code and a portal hypertensive 
complication (ascites, hepatic encephalopathy, or variceal bleeding).   
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Yearly prevalence was defined as the number of eligible ESI covered persons with cirrhosis in a given 
year who were covered throughout that year and whose index cirrhosis diagnosis date fell between 
January 1, 2009 and the last day of the year of interest (for example, prevalence for 2010 would 
include all cirrhosis diagnoses for 2009 as well as those occurring on or before December 31, 2010).  
Prevalence of cirrhosis in ESI US population by year was estimated by projecting the estimated 
number of MarketScan enrollees with cirrhosis to the national ESI population using weights derived 
from the Medical Expenditure Panel Survey (MEPS)(27).  MarketScan provides weights based on 5 
factors: age (<45 or ≥45), sex, census region, employee status, and Metropolitan Statistical Area 
(MSA), a standard unit of geographic analysis.  However, in 2015, Truven Analytics changed the 
weighting criteria, removing MSA.  In order to derive uniform weights across all years, we calculated 
weights for each year (2009-2015) using the four remaining MEPS factors: age (<45 or ≥45), sex, 
census region, and employee status (policy-holder versus covered dependent).  The ESI population 
was then stratified into 32 strata based on these factors and, for each year from 2009-2015, the ESI 
population size for each stratum was calculated using data from MEPS.  For each stratum, we 
determined the proportion of MarketScan subjects with a cirrhosis or AC code in a given year, and 
then multiplied these values by the corresponding ESI stratum size to obtain preliminary totals.  
Please see Supplemental Methods for further details.   
 
Two issues with limited time windows in administrative datasets can result in an overestimate of 
prevalence trends.  First, because cirrhosis patients enrolled over several years may go a year or 
longer between cirrhosis codes, prevalence estimates calculated by simply counting the number of 
cirrhosis cases based on encounters in a given year would be falsely low.  For example, an enrollee 
with continuous enrollment over several years may receive a diagnosis of cirrhosis without any other 
complications in 2009, not interact with the healthcare system in 2010, and reappear in the dataset in 
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2011 after receiving some type of healthcare.  Since cirrhosis does not go away, we would want to 
count this individual in our prevalence estimates for 2010.  Second, given that patients may be 
diagnosed with cirrhosis in the years before our data window (for example, 2007 or 2008), the early 
years of the data may be falsely low in prevalence, thus overestimating the slope of the overall trend.  
To account for these downward biases which underestimate yearly prevalence in the early years of 
the dataset and overestimate the time trend, we used standard methods for undercount adjustment in 
which we first estimated prevalence by determining the number of people with cirrhosis-related 
encounters in each year, then adjusted these numbers by a stratum-specific estimate of the 
undercounting due to missing people who had cirrhosis but had no claim in the given year. For 
detailed statistical methods, please see Supplementary Methods: Appendix B.  
 
Event rates analysis 
The primary event rates analysis used competing risks methodology to assess the time from 
diagnosis to onset of various cirrhosis complications, treating death as a competing event to 
complications, and censoring at loss of coverage(28).  Because portal hypertensive complications 
can co-occur and be present at the same time (as when a patient has both hepatic encephalopathy 
and a variceal bleed), the complications do not compete with each other and we estimate their rates 
separately.  Competing risks is used for analysis of deaths since each complication competes with 
death.  Determining the burden of portal hypertensive events after the index cirrhosis diagnosis 
requires adjusting for enrollees lost from the dataset due to loss of insurance coverage, change in 
employment, or transition to disability due to progressive illness. Competing risk analysis alone is 
sufficient when time to loss of coverage is independent of time to each event (“independent 
censoring”).  To accommodate any bias due to non-independent censoring, we performed an 
additional sensitivity analysis in which we fit a proportional hazards regression model using loss of 
coverage as the outcome with age and Elixhauser comorbidity scores as predictors(26). Event rates 
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were then estimated using stratified competing risks methodology with strata defined by individual risk 
for coverage loss(28).  We performed an additional sensitivity analysis of event rates among 
enrollees with AC but without hepatitis C, utilizing the same methodology.  
 
Overall Direct Healthcare Costs 
Direct healthcare costs result from tangible, billable services such as clinic visits, medications and 
hospitalizations. Indirect costs represent missed days of work or impaired quality of life, as examples.  
Cumulative direct costs for each person from index diagnosis date up to 12 months from cirrhosis 
diagnosis were calculated by summing the net payments to a provider across all claims. Co-
payments, co-insurance, and coordination of benefits fees were excluded.  Enrollees had to have 
coverage and be alive for at least one month post-diagnosis to be included in the cost analysis.  Per-
person costs were capped at 1 million US$ in the first year after diagnosis to exclude outliers resulting 
from inaccurate data entry. Values were log transformed and regressed against a variety of risk 
factors (portal hypertensive complications, Elixhauser, age, gender, census region, year of diagnosis 
as well as interactions amongst these variables).  Fitted costs were calculated at 1-year post-
diagnosis for enrollees who did not die within one year, and were calculated at the date of death 
otherwise.  The resulting fitted costs were then projected to the 2012 ESI population with national 
weights in the same method as described above. In determining which specific factors contributed to 
rising costs, we distinguished costs attributed to AC directly as well as costs associated with specific 
portal hypertensive complications using multivariable regression analysis, which allowed us to 
disaggregate the influences on costs of multiple cirrhosis-related complications, even when these 
complications co-occurred in a given enrollee.  
 
Overall admissions 
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Admissions were analyzed using similar statistical methods as discussed above for costs except 
negative binomial regression was used as appropriate for count data.  Admissions were subdivided 
into three main types based on primary diagnosis at admission: all-cause, cirrhosis-related, and 
alcohol-related.  Cirrhosis-related admissions were defined as hospitalizations in which the primary 
diagnosis was for either cirrhosis or a portal hypertensive complication, and for alcohol-related 
admissions, an alcohol-related diagnosis code (see Appendix A). The cumulative number of 
admissions from time of cirrhosis diagnosis through the first year after diagnosis was calculated for 
each enrollee.  Associations between risk factors of interest and admissions/readmissions were 
estimated using identical methods as above for costs.  Results are reported as differences in the 
number of admissions per 100 enrollees per year, contrasting two groups of interest (for example, 
comparing the number of admissions in the first year after diagnosis for 100 persons with AC to 100 
persons with non-AC).  30-day readmission rates following any admission type were calculated in a 
similar manner as for admissions. 
 
Results 
Prevalence of cirrhosis and AC in the privately insured (nationally adjusted ESI) US population 
Prevalence of all-cause cirrhosis in the privately insured US population based on the projected 
national ESI population increased by 42%, from 0.19% (236,349) in 2009 to 0.27% (294,215) 
(p<0.001) by 2015 (Figure 1).  During the same period, prevalence of AC increased by 43%, from 
0.07% to 0.10% (p<0.001).  In a sensitivity analysis, the prevalence of AC without HCV increased by 
44% (0.05% to 0.072%).  Persons age <45 had a more pronounced 300% increase from 0.01% to 
0.03% (p<0.001), compared to a 46% increase in those ≥45 years old (0.13% to 0.19%).  Women had 
a greater increase in prevalence of AC of 50% (0.04% to 0.06%) over 2009 to 2015, while men had a 
less pronounced increase of 30% (0.10% to 0.13%) (Figure 2).   
 
Characteristics of MarketScan enrollees with AC and non-AC at diagnosis  
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169,531 MarketScan enrollees had a cirrhosis diagnosis at some time during the period 2009-2015; 
of these, 66,053 (39%) had AC (see Table 1).  The median age at AC diagnosis was 53.5 years 
versus 53.0 years for non-AC. Notably, approximately one-third (32%) of those with AC and 49% of 
those with non-AC were women. At diagnosis, 19% of AC enrollees and 28% of non-AC enrollees 
had an HCV diagnosis. A higher proportion of enrollees with AC were decompensated compared to 
those with non-AC (28% vs 10%, p<0.001) (Table 1). The proportion with HCC between the two 
groups was similar at baseline (2% vs 2%).  AC enrollees had more comorbidities at diagnosis (2.63 
vs 2.30, p<0.001) compared to those with non-AC. 
 
Events in MarketScan enrollees with AC and those with non-AC    
The median duration of coverage was 688 days for enrollees with AC and 655 days for those with 
non-AC (p<0.001). The proportion with HCV diagnosis code increased in both groups, from 19% to 
29% in those with AC and from 28% to 35% in those with non-AC at 2 years after index cirrhosis 
diagnosis (Table 1). At 2 years post diagnosis, a significantly higher proportion of AC enrollees had 
portal hypertensive complications than those with non-AC though the rates of increase in both groups 
were similar. For example, ascites was diagnosed in 45% of AC enrollees and in 18% of those with 
non-AC (p<0.001) by 2 years’ post-cirrhosis diagnosis but the fold-increase were 2.0 and 2.4, 
respectively (Table 1).  Results were similar for sensitivity analyses accounting for dependent 
censoring (data not shown).  In an analysis comparing men with AC versus women with AC, women 
had slightly higher rates of decompensation at baseline (23% versus 21%) while men had higher 
rates of comorbid HCV (21% vs 14%) and HCC (2% vs <1%) at baseline (see Supplemental Table 1). 
 
In a sensitivity analysis comparing AC enrollees with and without comorbid HCV, those with cirrhosis 
attributed to alcohol alone had slightly higher rates of decompensation at baseline, but overall 
decompensation rates were similar at 2-years post-diagnosis (see Table 2). HCC, however, occurred 
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with greater frequency at baseline (1.7% vs 0.08%, p<0.001) and at 2-years post-diagnosis (8% vs 
4%, p<0.001) in those with versus those without comorbid HCV.  AC enrollees with comorbid HCV 
were also more likely to be transplanted at 2-years post-diagnosis (3% vs 2%, p<0.001, data not 
shown). 
 
Admissions and re-admissions in the MarketScan enrollees 
The projected annual all-cause admissions for the MarketScan enrolled cohort in 2015 for cirrhosis 
were 216,203, of which 107,501 (50%) were for those with AC.  AC enrollees had higher rates of all-
cause, cirrhosis-related, as well as alcohol-related admissions compared to those with non-AC.  
Mean per-person all-cause admissions in the first-year after diagnosis was 1.1 for AC compared to 
0.5 for non-AC.  AC had 58.5 excess all-cause admissions, 25 excess cirrhosis-related admissions, 
and 6.3 excess alcohol-related admissions per 100 enrollees per year compared to non-AC.  In 
regression models controlling for all demographic and baseline complications, AC contributed to 37% 
higher all-cause admissions (p<0.01) and 99% higher cirrhosis-specific admissions (p<0.01).  30-day 
readmissions were also higher for AC (30 excess all-cause readmissions per 100 enrollees per year).   
 
Direct healthcare costs for AC and non-AC in nationally weighted ESI population  
Overall direct healthcare costs in the nationally weighted ESI population for all cirrhosis was 9.5 
billion US$ in 2015 alone, with 53% of costs accrued by those with AC (5.04 billion US$) even though 
these enrollees only comprised 36% of the total cirrhosis population (see Figure 3).  Per-person 
healthcare costs for AC were markedly higher than for non-AC, with a mean of 44,835 US$ per 
person in the first year after index diagnosis compared to 23,319 US$ for non-AC.  In a sensitivity 
analysis of AC without HCV, mean per-person costs were slightly attenuated at 39,299 US$ for AC 
without HCV. Mean per-person healthcare costs in the first year after index cirrhosis diagnosis were 
higher for those with decompensated cirrhosis (68,982 US$ vs 12,316 US$) compared to those 
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without decompensation. Decompensating events, admissions and readmissions were significantly 




In this large cohort of private, employer-sponsored insured cirrhosis persons, AC made up just over 
one-third of the total cirrhosis burden in the nationally weighted ESI population in the US, consumed 
just over half the overall direct healthcare expenditures among persons with cirrhosis, and had 
healthcare costs nearly double their non-AC counterparts. AC enrollees presented with more portal 
hypertensive complications and had similar rates of disease progression during the follow-up period.  
They were also more frequently admitted and readmitted even after covariate adjustment. 
 
Our overall cirrhosis prevalence of 0.27% is consistent with the findings of the US National Health 
And Nutrition Examination Survey (NHANES)(15), but our data highlight the burden of AC which was 
not directly assessed in the NHANES study.  We found that AC accounted for 37% of all cirrhosis 
giving a national ESI AC prevalence of 0.10%, or approximately 100 people with AC per 100,000 
people with ESI. Studies in the Department of Veteran’s Affairs (VA) health care system in 2013 
demonstrated a higher cirrhosis prevalence of 1.03%, with AC making up 30%.  In that study, 
however, 61% of those with HCV had comorbid AC and these patients were coded as HCV cirrhosis 
and not AC, resulting in an underestimate of the attributable burden of AC in the VA population(18).  
A recently published study showed decreasing prevalence of AC, despite rising rates of liver 
transplantations done for ALD(1).  Similar to the VA study, this study classified all AC with HCV as 
HCV cirrhosis and not AC. Excluding AC with comorbid HCV or nonalcoholic fatty liver disease 
(NAFLD) underestimates the attributable burden of ALD and masks its importance as a driver of 
progressive liver disease(29). To obtain accurate estimates of ALD burden, future studies should 
report overall liver disease burden related to alcohol use and the contributions of comorbid HCV.   
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Our data adds to and extends the literature on cirrhosis prevalence by focusing specifically on AC 
prevalence, as well as determining cirrhosis and AC prevalence in the national ESI population drawn 
from a well-characterized dataset of administrative claims, the Truven MarketScan database.  This 
large-scale national database of private employer-sponsored insured US adults has been widely used 
to estimate disease prevalence, outcomes, and costs for a number of disease conditions, including 
gastroenterological diseases.(19-22) With nearly half the US population obtaining insurance via their 
employer, the scope of MarketScan enrollment, which includes >100 million individual covered lives 
with half a billion claims over multiple years, allows for such large-scale estimates and greater 
generalizability to a broader subset of the US population.  Importantly, since AC has been shown to 
represent more than half of all US inpatient cirrhosis-related admissions while only 23% of cirrhosis 
discharges had private insurance, our data likely understates the overall burden of ALD amongst the 
entire US population and represents the best case scenario for AC in the US(30,31). The true 
prevalence of AC in the US may be much higher when accounting for Medicare and Medicaid 
patients, particularly given that many patients with cirrhosis are 65 or older and were excluded from 
our study.  Though recently reversed, the Center for Medicare and Medicaid (CMS) had previously 
eliminated all substance use disorder claims from their available datasets, thus limiting analysis of 
substance-related medical disease like ALD in persons covered by Medicare or Medicaid(16).  Many 
AC patients are Medicaid-insured due to low income and socioeconomic status, and as many as 50% 
of them will lose eligibility yearly due to income fluctuations, making large-scale national analyses of 
this population over time challenging(17).  Even within our well-characterized cohort, AC prevalence 
may be underestimated due to failure to recognize an alcohol etiology, which has been shown to 
occur in other studies where mortality from ALD was under-estimated by two-fold due to patient 
concealment and stigma(5).  In addition, alcoholic hepatitis, which is also associated with high costs, 
readmissions, and mortality, is poorly ascertained using diagnostic coding and were excluded from 
this analysis except for those with a cirrhosis code, thus underestimating the burden of advanced 
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The burden of cirrhosis in the US has not been given the same priority as other high-cost diseases, 
such as cancer, because of lower prevalence. However, burden of disease should be compared on 
the basis of similar mortality risks and resource utilization. The prevalence of AC and non-AC is 
comparable to or surpasses that of lung and colorectal cancers (0.13% and 0.33%, respectively)(33).  
One-year mortality rates for decompensated AC patients are 29-64%, compared to 11-12% for 
colorectal cancer patients and 50% for lung cancer patients aged 18-64(33).  The costs of AC and 
non-AC also approximate the range of per-person yearly costs of cancer patients regardless of 
treatment (21,000 US$ to 90,000 US$ in commercially insured persons)(34).  Our estimates of yearly 
costs of managing decompensated cirrhosis, hepatorenal syndrome and HCC are similar to 
previously published cost estimates supporting the robustness of our cost estimates(35-37).  In 
studies of the global burden of AC, its disability-adjusted life year (DALY) burden exceeded that of 
other alcohol-related malignancies(38). The global burden of AC is likewise high, estimated at 12.8% 
of total healthcare costs and 2.5% of total Gross Domestic Product (GDP) in high-income countries 
and 5.6% and 2.1%, respectively in middle-income countries(38).   
 
Our study showed an increase in AC prevalence in all age groups during the study period 2009-2015, 
with a more pronounced increase amongst enrollees <45 years old as well as a greater rate of 
increase amongst women.  Although some of the increase may be related to diagnostic coding 
limitations (i.e. the diagnosis might be present but not entered until after the subject had been 
followed for a time), we adjusted prevalence results to mitigate this bias. Other studies have shown 
an increase in non-cirrhotic ALD prevalence. One study showed an increase in prevalence of non-
cirrhotic ALD from 1.38% to 2.05% from 1988 to 2008 with projected AC soon comprising the largest 
portion of the cirrhosis and liver transplant burden(14,30).  Increases in prevalence and mortality had 
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also been reported for non-AC patients(13,30).  The rise in AC for younger persons has implications 
for indirect costs as well, including early mortality and decreased work productivity, as well as 
continued higher direct health-care costs and utilization in subsequent years should these young 
persons survive.  The higher rate of increase in AC amongst women (50% vs 30% for men over 
2009-2015) mirrors the rise in AUDs recently reported in the US population, where women 
experienced an 80% increase in rates of AUDs compared to 30% for men(11). This is particularly 
concerning given that the hepatotoxic dose of alcohol for women is lower than that for men(11).  
These rising rates of AUDs in women will likely worsen existing rising trends in cirrhosis and 
substance abuse-related mortality for middle-aged women, rates which are already at historically high 
levels (13).  With these rising rates, increased attention to early diagnosis of ALD and AC in women 
will be needed. In particular, attention to developing AUD treatment options tailored for women’s 
preferences and helping both women and men connect to alcohol use treatment will be critical in 
improving outcomes for this population.    
 
A striking finding of our study was the disproportional cost burden of AC comprising just over half of 
the total direct healthcare costs for cirrhosis while representing only 36% of all cirrhosis.  Further, the 
per-person costs were nearly double that of non-AC.  Much of this cost burden was attributable to 
significantly higher rates of portal hypertensive complications, as well as admissions and 
readmissions in AC enrollees, findings which support previously published data from AC patients in 
Europe and the US, though our cost findings are novel with respect to privately insured US AC and 
non-AC populations(2).  While reasons for the higher prevalence of portal hypertensive complications 
at diagnosis in AC enrollees are not fully clear from our data, delayed diagnosis of ALD prior to 
cirrhosis, delays by patients with alcohol use disorders in seeking medical care, and ongoing alcohol 
use despite the presence of liver disease may be contributory as the higher prevalence of portal 
hypertensive complications at index diagnosis persisted in sensitivity analyses controlling for 
comorbid HCV.  Our data suggest that the costs of AC will continue to increase unless measures are 
Page 15 of 35
Hepatology
Hepatology












implemented to find and treat AC patients earlier by facilitating alcohol abstinence, the most effective 
intervention to halt liver disease progression(4).  Admissions and readmissions for AC were likewise 
higher than for non-AC, contributing to the cost burden.  Our findings confirm data from the 
Healthcare Utilization Project, a large well-characterized dataset of nationally-representative hospital 
discharges, which similarly showed that AC patients make up the majority of cirrhosis-related 
discharges(39). Higher admission rates among AC enrollees in our study were driven not only by 
liver-related admissions but also alcohol-related admissions, highlighting the unique importance of 
alcohol use interventions and treatment.   
 
Our study has several limitations. First, the nature of private insurance administrative claims data 
means that patients can be lost from the dataset due to change in or loss of employment.  However, 
our robust statistical methodology included multiple techniques to account for complicating factors 
such as dependent censoring, unequal duration of pre- and post-diagnosis follow-up, and changing 
representation of the ESI population in MarketScan data.  Second, the movement towards capitated 
claims could result in underestimation of costs, as capitated services are poorly represented in fee-
for-service claims data.  Third, MarketScan data does not include race or ethnicity information, 
precluding an analysis of racial disparities in AC burden.  Fourth, ALD codes have not been validated 
in administrative datasets.  Our cirrhosis and portal hypertension codes, however, are well-validated 
with positive predictive values >80% and alcohol use ascertainment codes in our study have been 
previously used in large-scale estimates of cirrhosis burden(18,24).  Several validation studies for 
cirrhosis in non-VA administrative data have concluded that to maximize both sensitivity and 
specificity, codes for both cirrhosis as well as portal hypertensive complications must be included in 
the coding algorithm (24,40).  Such coding algorithms, while highly specific for decompensated 
cirrhosis, exclude compensated cirrhosis.  Furthermore, this coding strategy would miss enrollees 
with alcoholic hepatitis, who do not have a cirrhosis code.  As such, our coding strategy favored 
specificity and positive predictive value to ensure that the accuracy of cirrhosis in the cohort was high. 
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We acknowledge that this strategy may miss some persons with as yet undiagnosed compensated 
cirrhosis and some persons with alcoholic hepatitis and underestimate the overall burden of cirrhosis 
and ALD.   
 
In conclusion, our study shows a high burden of AC in the private ESI US population, which increased 
further in recent years with a more pronounced increase amongst women.  Persons with AC are 
sicker at presentation, admitted and re-admitted more frequently for liver- and alcohol-related 
reasons, and incur twice the healthcare costs as their non-AC counterparts. Our results highlight the 
urgent need to more effectively detect and prevent ALD and, even more importantly to aid ALD 
patients in achieving and maintaining alcohol abstinence given its key role in improving morbidity and 
mortality in ALD.  
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Table 1.  Demographic characteristics and prevalence of portal hypertensive complications. 




















Median age at 
diagnosis (years)  
(Range 19-64) 
53.5 53.0     
Female 21,442 (32%) 50,196 (49%)     
Mean Coverage 
Duration (days) 
688 655     
Elixhauser 2.63 2.30     
HCV 12,550 (19%) 28,973 (28%) 27% 33% 29% 35% 
Ascites 14,531 (22%) 8,278 (8%) 38% 14% 45% 18% 
Hepatic 
Encephalopathy 
3,963 (6%) 1,035 (1%) 19% 5%  26% 7% 
Variceal bleeding 2,642 (4%) 1,035 (1%) 10% 4%  13% 5% 
GI Bleeding 10,568 (16%) 8,278 (8%) 29% 14% 35% 18% 
HCC 1,321 (2%) 2,069 (2%) 5% 5% 8% 6% 
SBP 396 (<1%) 103 (<1%) 4% 1% 5% 1% 
HRS 528 (<1%) 103 (<1%) 4%  1% 6% 2% 
AKI 5,284 (8%) 4,139 (4%) 19% 9% 26% 12% 
Decompensation
@ 




19,155 (29%) 43,460 (42%) 56% 60% 62% 64%  
Liver transplant 13 (<1%) 36 (<1%) 1% 1% 3% 1% 
AC: alcoholic cirrhosis; HCV: Hepatitis C virus; HCC: hepatocellular carcinoma; SBP: spontaneous bacterial peritonitis; HRS: 
hepatorenal syndrome; AKI: acute kidney injury *P<0.05 for all between-group comparisons (AC versus non-AC).  
§
Gastroenterology 
outpatient visits were defined as a single code for an outpatient visit with a GI specialist. 
@
Decompensation defined as at least 1 
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Table 2.  Portal hypertensive event rate analysis at index diagnosis, 1- and 2-years post-diagnosis comparing 
alcoholic cirrhosis (AC) enrollees with and without comorbid hepatitis C (HCV).  
Event Baseline 
N= 66,053 AC patients 















Ascites 3,951 (21%) 10,864 (23%) 38% 39% 45% 44% 
Hepatic 
Encephalopathy 
1,053 (5.6%) 2,928 (6.2%) 19% 19% 26% 25% 
Hepatorenal 
syndrome 
188 (1%) 377 (0.08%) 4.3% 4.4% 6.3% 6.0% 
Variceal Bleed 677 (3.6%) 1,700 (3.6%) 9.8% 9.2% 13% 12% 
Hepatocellular 
carcinoma 
319 (1.7%) 377 (0.08%) 5.5% 2.6% 8% 4% 
GI bleeding 2,822 (15%) 8,030 (17%) 29% 29% 35% 35% 
Spontaneous 
Bacterial Peritonitis 
112 (0.06%) 283 (0.06%) 3.6% 3.3% 5.4% 4.7% 
Decompensation
@ 
5,268 (28%) 14,170 (30%) 47% 47% 54% 53% 
@
Decompensation defined as at least 1 occurrence of ascites, hepatic encephalopathy, or variceal bleeding. 
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Table 3.  Mean estimated per-person costs in US dollars over 1 year post-diagnosis in enrollees with and 
without alcoholic cirrhosis.   
 
Condition Present Absent 
Alcoholic cirrhosis* $44,835 $23,319 
Alcoholic cirrhosis without comorbid HCV $39,299 $25,652 
Ascites# $77,545 $13,791 
Variceal bleed# $80,745 $25,271 
Hepatic encephalopathy# $108,838 $19,534 
Hepatocellular carcinoma# $101,718 $25,656 
Hepatorenal syndrome or Acute kidney 
injury# 
$131,937 $18,127 
Spontaneous bacterial peritonitis# $177,183 $25,650 
Liver transplant# $436,813 $24,840 
*Cost of alcoholic cirrhosis (inclusive of those with comorbid HCV) vs non-alcoholic cirrhosis regardless of presence or absence of 
portal hypertensive complications, HCV, hepatocellular carcinoma and liver transplant  
#
Cost of portal hypertensive complications, hepatocellular carcinoma and liver transplant regardless of etiology of cirrhosis: alcohol vs 
non-alcohol
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tSupplementary Appendix A. ICD-9 and ICD-10 codes used for cohort selection and comorbidities  Disease ICD-10 Code  (started 10/1/2015) ICD-9 Code 
Cirrhosis K74.6x 571.5 
Alcohol use F10.x, T51.x, K86.0, 
I42.6, K29.20, K29.21, 
G62.1 
790.3, 425.5, 535.30, 
535.51, 577, 357.5, 
291.x, 303.x, 305.0x, 
V113.0, E860.01-.03, 
980.x 






571.1, 571.2, 571.3 
 
571.2 
Upper GI bleed 
 
K29.01, K29.21, K29.31, 
K29.41, K29.51, K29.61, 
K29.71, K29.81, K29.91, 
I85.01, I85.11, K22.11, 
K26.0, K26.2, K26.4, 
K26.6 
456.0, 456.2, 530.82, 
530.00, 530.01, 531.20, 
531.21, 531.40, 531.41, 
531.60, 531.61, 532.00, 
532.01, 532.21, 532.40, 
532.41, 532.60, 532.61, 
533.00, 533.01, 533.20, 
533.21, 533.40, 533.41, 
533.60, 533.61, 534.00, 
534.20, 534.21, 534.40, 
534.41, 535.01, 535.11, 
535.21, 535.31, 535.41, 
535.51, 535.61, 537.83, 
578.0, 578.1, 578.9,  
Hepatitis C B18.2 070.41, 070.44, 070.51, 
070.54, 070.70, 070.71 
Ascites R18.8, K71.51 789.59, 789.50 
Varices without bleed I85.00, I85.10 456.1, 456.21 
Variceal bleed I85.01, I85.11 456.0, 456.2 
Portal hypertension K76.6 572.3 
Hepatic encephalopathy K72.91 572.2 




Diabetes E08.xx, E10.xx, E11.xx, 
E13.xx 
250.x 
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More specific alcohol use codes and definitions: 
 
ICD-9 Codes Definitions 
790.30 Excessive blood alcohol level 
425.5 Alcoholic cardiomyopathy 
535.30, 535.31 Alcoholic gastritis, with and without bleeding 
577 Alcoholic pancreatitis 
357.5 Alcoholic polyneuropathy 
291.x Alcohol-induced mental disorders 
303.x Alcohol dependence syndromes 
980.x Toxic effect of alcohol  
305.0x Nondependent alcohol abuse 
E860.0, E860.1 Accidental poisoning by alcohol 
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tSupplementary Table 1.  Event rate analysis at index diagnosis, 1- and 2-years post-diagnosis comparing alcoholic cirrhosis enrollees with and without comorbid hepatitis C.  Event Baseline 1 year 2 year 
With HCV Without 
HCV 
With HCV Without 
HCV 
With HCV Without 
HCV 
Ascites 22% 23% 38% 39% 45% 44% 
Hepatic 
Encephalopathy 
6% 6% 19% 19% 26% 25% 
Hepatorenal 
syndrome 
1% 1% 4% 4% 6% 6% 
Variceal Bleed 4% 4% 10% 9% 13% 12% 
Hepatocellular 
carcinoma 
2% 1% 6% 3% 8% 4% 




<1% <1% 4% 3% 5% 5% 
Decompensation@ 28% 30% 47% 47% 54% 53% 
Liver transplant <1% <1% 1% 1% 3% 2% 
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tAppendix B: Supplementary Methods Prevalence estimation 
For prevalence estimation, the ESI population was stratified into 32 strata based on the following four factors: 
age (18-45 or 45-64), sex, census region (4 categories), and employee status (policy holder versus covered 
dependent).  For each of these strata, and for each year from 2009-2015, the total ESI population size was 
calculated from the Medical Expenditure Panel Survey(1).  For each stratum, we estimated the cirrhosis or 
ALD/cirrhosis prevalence in Marketscan as discussed below, and then multiplied this prevalence estimate by 
the corresponding ESI stratum size to determine a per-stratum population count.  These counts were then 
summed to produce an overall estimated prevalence count per year.  This prevalence count was then divided 
by the ESI population size to produce a prevalence rate. 
 
Estimation of the per-stratum Marketscan ESI prevalence is complicated by the need to reduce bias resulting 
from differing lengths of observation among the subjects.  If we consider a person’s cirrhosis status on a 
particular date to be determined by having had a cirrhosis code on or prior to that date in our data, the 
prevalence estimates for the earlier years will be biased downward, due to shorter lengths of preceding data.  
This leads to two potential areas of bias in the data: 1) under-reported prevalence and 2) an artificially steep 
estimate of trend increase.  The first bias, of under-reported prevalence, is due to subjects being diagnosed 
with cirrhosis in one year, remaining enrolled in the dataset but not interacting with the healthcare system in 
subsequent years, and then re-appearing in the dataset once a claim is entered (for example, a patient is 
diagnosed with cirrhosis in 2009, remains enrolled but does not interact with the healthcare system in 2010, 
and then does so in 2011 when a claim appears in the dataset).  Because cirrhosis is a chronic condition that 
does not wax and wane but, once present remains present, failure to account for these “skipped” years would 
produce artifically low prevalence estimates.  The second bias results from underestimation of cirrhosis 
prevalence in the early years of the cohort because we are unable to include patients with diagnoses in 2008 
or earlier, which is outside our dataset window.  This produces an artificially steep estimate of the rate of 
increase in cirrhosis prevalence, since the later years in our data record will be less biased than the earlier 
years.  
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tTo mitigate these two biases, we adjusted results as follows: To estimate yearly cirrhosis prevalence, for each year from 2009-2015 we selected the people who were enrolled for the entire year, and directly calculated the proportion of these people who had a cirrhosis code during that year in each stratum.  These rates 
underestimate the true prevalences since people with cirrhosis can go a year or longer without receiving a 
cirrhosis code, as discussed above, even while they remain covered.  Therefore, we used the 2015 data to 
estimate the downward bias in this rate so that we can correct for it.  We considered everyone who was 
covered for all of 2015 (the year for which we have the greatest length of historical data) and then calculated 
two rates: one based on subjects having a cirrhosis code in 2015, and one based on subjects having a 
cirrhosis code in any year from 2009-2015.  The ratio of these rates (approximately 1.7) reflects the undercount 
when considering only people who have cirrhosis codes in a particular year.  To produce our final prevalence 
estimates, we adjusted the per-stratum Marketscan counts by this factor prior to projecting them to the ESI 
population.   
 
Cost analysis 
Raw per-person costs were calculated by summing the “netpay” values in the Marketscan O, S, and D tables.  
Costs were summed over the first year following diagnosis, capping the total cost at 1 million dollars.  A “time” 
value was calculated as the duration of coverage from diagnosis up to 1 year.  Subjects who lost coverage or 
who died during the first year were coded with time equal to their coverage/survival duration, all other subjects 
had time=1.  We then fit linear regression models to model the costs as a function of numerous controls.  
Forward variable selection was used to select main effects and interactions from the following variables: year 
of diagnosis, time (as described above), female, age at diagnosis, Elixhauser score, ascites, variceal bleed, 
hepatic encephalopathy, alcoholic liver disease, gastrointestinal bleeding,  liver cancer, hepatitis C, HRS or 
AKI, portal hypertension, liver transplant, SBP, and census region.  All time-varying covariates were coded 
based on their value at the end of the cost-summation period (1 year for most subjects).  The final model had 
32 terms in all.  We then used the fitted values from this model to produce a modeled cost for each Marketscan 
person.  When forming these fitted values, the time variable was reset to 1 for everyone who did not die 
(thereby accounting for censoring), but remained at the survival duration for people who died.   
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t These predicted log costs were then averaged within subgroups of interest using 2012 weights (derived as in the prevalence analysis) to account for discrepancies between the Marketscan and ESI populations.  
Subgroups of interest included, for example, subjects who do and who do not have ascites during their first 
year post-diagnosis.  This allowed us to compare average per-person costs for these subgroups in a way that 
reflects the ESI population, and is minimally biased due to differing follow-up times.  These cost estimates do 
not attempt to isolate a given risk factor from other factors that correlate with it.  For example, the difference in 
mean costs between people with and without ALD is inflated by costs of ALD-associated comorbidities, such 
as ascites or variceal bleeding.   
 
We also calculated regression effects for factors of interest, expressing the results as the percent change in 
cost associated with each risk factor.  Since the regression analysis considers cost on the log-scale, 
associations between individual factors, such as ascites, and costs can be calculated directly from the 
regression slopes, and presented as percent changes, e.g. the percentage difference in total costs associated 
with having, versus not having ascites.  
Admissions and readmissions analysis 
The admissions and readmissions analyses used a similar model-based strategy as the cost analyses.  
Negative binomial regression models were used for admission counts in place of the linear model used in the 
cost analysis.  Regression effects, controlling for all other modeled factors were estimated as in the cost 
analysis.  In addition, comparisons between risk groups of interest were conducted in two ways.  First, as in the 
cost analysis, the weighted mean modeled admissions counts in two subgroups were computed, e.g. for 
comparing people who do and who do not have ascites within the first year after cirrhosis diagnosis.   The 
results are presented as excess events per 100 subjects, meaning the difference between the number of 
admissions for 100 subjects with ascites and for 100 subjects without ascites.  These differences are referred 
to as the “excess admissions per 100 cases”.  Note that these comparisons are influenced by the factor of 
interest (e.g. ascites) and by other risk factors correlated with it.  
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Supplementary Table 1.  Gender and portal hypertensive complication event rates. 
	










































HCV 21% 14% 35% 20% 30% 21% 42% 24% 32% 23% 43% 25% 
Ascites 21% 23% 8% 7% 38% 40% 15% 14% 45% 46% 18% 17% 
Hepatic 
Encephalopathy 
5.3% 6.2% 1.2% 1.3% 19% 20% 5%  5% 26% 26% 7% 7% 
Variceal bleeding 4,2% 2.3% 1,3% 1.0% 11% 7.6% 4%  3.1% 15% 11% 5% 4.5% 
GI Bleeding 16% 14% 8% 7% 29% 27% 14% 13% 36% 33% 18% 17% 
HCC 2% <1% 3% 1.3% 7% 3% 7% 3% 9.4% 4% 9% 4% 
SBP <1% <1% <1% <1% 4% 4% 1% 1% 6% 5% 2% 1% 
HRS <1% 1% <1% <1% 4%  4% 1% 1% 6% 6% 2% 1% 
AKI 8% 8% 5% 3% 20% 18% 10% 8% 27% 24% 13% 10% 
Decompensation@ 27% 29% 10% 9% 47% 47% 19% 17% 55% 53% 23% 21% 
AC: alcoholic cirrhosis; HCV: Hepatitis C virus; HCC: hepatocellular carcinoma; SBP: spontaneous bacterial peritonitis; HRS: hepatorenal syndrome; AKI: acute kidney injury 
*P<0.05 for all between-group comparisons (AC versus non-AC).  §Gastroenterology outpatient visits were defined as a single code for an outpatient visit with a GI specialist. 
@Decompensation defined as at least 1 occurrence of ascites, hepatic encephalopathy, or variceal bleeding. 
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